120
Participants
Start Date
September 8, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
March 1, 2026
Liposomal bupivacaine
Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
Bupivacaine
Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
RECRUITING
NorthShore University HealthSystem, Skokie
Collaborators (1)
Endeavor Health
OTHER
Johnny K. Lee
OTHER